NYSE:MYOV - Myovant Sciences Stock Price, News, & Analysis

$9.20
-0.07 (-0.76 %)
(As of 06/19/2019 02:43 PM ET)
Today's Range
$9.01
Now: $9.20
$9.26
50-Day Range
$8.66
MA: $12.72
$18.44
52-Week Range
$8.52
Now: $9.20
$27.45
Volume6,967 shs
Average Volume550,514 shs
Market Capitalization$664.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:MYOV
CUSIPN/A
Phone441-295-5950

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-273,550,000.00

Miscellaneous

Employees86
Market Cap$664.24 million
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd (NYSE:MYOV) issued its earnings results on Thursday, February, 7th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.06. View Myovant Sciences' Earnings History.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Myovant Sciences.

What price target have analysts set for MYOV?

7 brokers have issued 1 year target prices for Myovant Sciences' stock. Their predictions range from $25.00 to $39.00. On average, they expect Myovant Sciences' share price to reach $27.80 in the next year. This suggests a possible upside of 202.2% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

What is the consensus analysts' recommendation for Myovant Sciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

Has Myovant Sciences been receiving favorable news coverage?

Headlines about MYOV stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myovant Sciences earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the stock's share price in the next several days. View News Stories for Myovant Sciences.

Are investors shorting Myovant Sciences?

Myovant Sciences saw a increase in short interest in May. As of May 15th, there was short interest totalling 2,043,300 shares, an increase of 16.6% from the April 15th total of 1,752,600 shares. Based on an average trading volume of 133,800 shares, the days-to-cover ratio is presently 15.3 days. Approximately 10.3% of the shares of the stock are short sold. View Myovant Sciences' Current Options Chain.

Who are some of Myovant Sciences' key competitors?

What other stocks do shareholders of Myovant Sciences own?

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:
  • Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)
  • Mr. Frank L. Karbe, Chief Financial Officer (Age 51)
  • Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)
  • Ms. Julie Tran MBA, MSHR, Sr. VP of HR
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51)

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (3.54%), Victory Capital Management Inc. (1.19%) and Emory University (0.16%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Institutional Ownership Trends for Myovant Sciences.

Which institutional investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC and Emory University. View Insider Buying and Selling for Myovant Sciences.

Which institutional investors are buying Myovant Sciences stock?

MYOV stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Insider Buying and Selling for Myovant Sciences.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $9.20.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $664.24 million. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is http://myovant.com/.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 441-295-5950 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel